Since 2017, combination treatment with the anti-angiogenesis targeting agent of lenvatinib and anti-programmed cell death protein 1 (PD-1) antibodies, has achieved high therapeutic response rates for HCC and BTC (10). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.